ArticleWorld journal of surgery2016
Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic Cancer.
Article in World journal of surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- PDGFR-βAging · 2021Pooled it
- Dual-layer spectral detector CT: a non-invasive tool for simultaneously predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma.Abdominal radiology (New York) · 2026Article
- Interaction of Avapritinib with Congo Red in Pancreatic Cancer Cells: Molecular Modeling and Biophysical Studies.International journal of molecular sciences · 2025Article
- Functional and clinical roles of stromal PDGF receptors in tumor biology.Cancer metastasis reviews · 2024Review
- Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study.Biomarkers in medicine · 2024Article
- Primary cilia-associated signalling in squamous cell carcinoma of head and neck region.Frontiers in oncology · 2024Review
- Epigenetic control of pancreatic cancer metastasis.Cancer metastasis reviews · 2023Review
- Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.International journal of clinical oncology · 2023Article
- Anticancer Activity of Sunitinib Analogues in Human Pancreatic Cancer Cell Cultures under Normoxia and Hypoxia.International journal of molecular sciences · 2023Article
- Current Pathology Model of Pancreatic Cancer.Cancers · 2022Review
- HDAC2 Facilitates Pancreatic Cancer Metastasis.Cancer research · 2022Article
- Review
- Relevance of gene mutations and methylation to the growth of pancreatic intraductal papillary mucinous neoplasms based on pyrosequencing.Scientific reports · 2022Article
- Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors.Scientific reports · 2021Article
- Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.Theranostics · 2021Review
- UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy.Journal of Cancer · 2021Article
- Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor ReceptorMolecules (Basel, Switzerland) · 2020Article
- Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.Gut · 2019Review
- Expression of CAF-Related Proteins Is Associated with Histologic Grade of Breast Phyllodes Tumor.Disease markers · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentifying novel predictors of hematogenous metastasis is essential to select optimal therapeutic strategies for pancreatic cancer. The goal of this study was to clarify the clinical implications of p53 and platelet-derived growth factor receptor-β (PDGFR-β) in pancreatic cancer using immunohistochemistry (IHC).
methodsSpecimens obtained by surgical resection and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of the primary tumor were used for IHC. EUS-FNA was performed before any treatment. We analyzed the clinical implications of p53 and PDGFR-β IHC. We also performed a comparative analysis of the IHC findings between surgical and EUS-FNA specimens.
resultsThis study involved 149 patients (120 who did not receive and 29 who received preoperative therapy). EUS-FNA specimens were obtained from 20 patients without preoperative therapy and 20 patients with preoperative therapy. Abnormal p53 and high PDGFR-β expression was significantly correlated with a high incidence of hematogenous metastasis (p < 0.001) and poor postoperative survival (p = 0.006). In patients without preoperative therapy, the results for p53 and PDGFR-β staining were concordant between surgical and EUS-FNA specimens in 95 % of the cases. In patients with preoperative therapy, 80 and 70 % of the patients showed consistent p53 and PDGFR-β expression between surgical and EUS-FNA specimens, respectively.
conclusionsPancreatic cancer patients with simultaneous abnormal p53 and high PDGFR-β expression have a significantly higher risk of hematogenous metastasis and a poor prognosis after surgery. IHC evaluation using EUS-FNA specimens may be able to identify patients with highly metastatic pancreatic cancer who may benefit from aggressive therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.